U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H28O3
Molecular Weight 340.4559
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NORETHINDRONE ACETATE

SMILES

[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(C)CC[C@]3([H])[C@@]4([H])CCC(=O)C=C4CC[C@@]23[H]

InChI

InChIKey=IMONTRJLAWHYGT-ZCPXKWAGSA-N
InChI=1S/C22H28O3/c1-4-22(25-14(2)23)12-10-20-19-7-5-15-13-16(24)6-8-17(15)18(19)9-11-21(20,22)3/h1,13,17-20H,5-12H2,2-3H3/t17-,18+,19+,20-,21-,22-/m0/s1

HIDE SMILES / InChI

Molecular Formula C22H28O3
Molecular Weight 340.4559
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/8520623 https://www.medicines.org.uk/emcmobile/PIL.23891.latest.pdf http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018405s023lbl.pdf

Norethisterone (INN, BAN), also known as Norethindrone (USAN) (brand names Micronor, AYGESTIN, numerous others) is a synthetic progestational hormone (progestin) with actions similar to those of progesterone but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. AYGESTIN® is not intended, recommended or approved to be used with oncomitant estrogen therapy in postmenopausal women for endometrial protection. Progestins diffuse freely into target cells and bind to the progesterone receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge. Allergic reaction could be: Itching or hives, swelling in your face or hands, swelling or tingling in your mouth or throat, chest tightness, trouble breathing.

CNS Activity

Curator's Comment: Known to be CNS penetrant in rat. Human data not available Norethindrone affects the levels of opioid petides in the rat brain, but it is not clear whether this action is mediated by direct activity within CNS

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
6.8 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
MICRONOR

Approved Use

Indications Progestin-only oral contraceptives are indicated for the prevention of pregnancy. 2. Efficacy If used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.5%. However, the typical failure rate is estimated to be closer to 5%, due to late or omitted pills. Table 1 lists the pregnancy rates for users of all major methods of contraception. Table 1: Percentage of Women Experiencing an Unintended Pregnancy During the First Year of Typical Use and the First Year of Perfect Use of Contraception and the Percentage Continuing Use at the End of the First Year. United States. Adapted from Hatcher et al, 1998, Ref. #1 Emergency Contraceptive Pills: Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%The treatment schedule is one dose within 72 hours after unprotected intercourse, and a second dose 12 hours after the first dose. The Food and Drug Administration has declared the following brands of oral contraceptives to be safe and effective for emergency contraception: Ovral® (1 dose is 2 white pills), Alesse® (1 dose is 5 pink pills), Nordette® or Levlen® (1 dose is 2 light-orange pills), Lo/Ovral® (1 dose is 4 white pills), Triphasil ® or Tri-Levlen® (1 dose is 4 yellow pills) Lactational Amenorrhea Method: LAM is highly effective, temporary method of contraceptionHowever, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches six months of age. Source: Trussell J, Contraceptive efficacy. In Hatcher RA, Trussel J, Stewart F, Cates W, Stewart GK, Kowal D, Guest F, Contraceptive Technology: Seventeenth Revised Edition. New York NY: Irvington Publishers, 1998. % of Women Experiencing an Unintended Pregnancy within the First Year of Use % of Women Continuing Use at One Year Among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year Method (1) Typical UseAmong typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason (2) Perfect UseAmong couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason (3) (4) ChanceThe percents becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within one year. This estimate was lowered slightly (to 85%) to represent the percent who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether 85 85 SpermicidesFoams, creams, gels, vaginal suppositories, and vaginal film 26 6 40 Periodic abstinence 25 63 Calendar 9 Ovulation Method 3 Sympto-Thermal Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases 2 Post-Ovulation 1 CapWith spermicidal cream or jelly Parous Women 40 26 42 Nulliparous Women 20 9 56 Sponge Parous Women 40 20 42 Nulliparous Women 20 9 56 Diaphragm 20 6 56 Withdrawal 19 4 CondomWithout spermicides Female (Reality®) 21 5 56 Male 14 3 61 Pill 5 71 Progestin Only 0.5 Combined 0.1 IUD Progesterone T 2.0 1.5 81 Copper T380A 0.8 0.6 78 LNg 20 0.1 0.1 81 Depo-Provera® 0.3 0.3 70 Norplant® and Norplant-2® 0.05 0.05 88 Female Sterilization 0.5 0.5 100 Male Sterilization 0.15 0.10 100 Norethindrone tablets have not been studied for and are not indicated for use in emergency contraception.

Launch Date

1973
Primary
AYGESTIN

Approved Use

AYGESTIN® is indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. AYGESTIN® is not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection.

Launch Date

1982
Primary
AYGESTIN

Approved Use

AYGESTIN® is indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. AYGESTIN® is not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection.

Launch Date

1982
Primary
AYGESTIN

Approved Use

AYGESTIN® is indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. AYGESTIN® is not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection.

Launch Date

1982
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
26.19 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORETHINDRONE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
166.9 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORETHINDRONE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.51 h
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORETHINDRONE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3%
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORETHINDRONE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
15 mg 1 times / day multiple, oral
Studied dose
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, 10.2-41.9 years
Health Status: unhealthy
Condition: Endometriosis
Age Group: 10.2-41.9 years
Sex: F
Sources:
Other AEs: Weight gain...
Other AEs:
Weight gain
Sources:
20 uCi single, intravenous
Dose: 20 uCi
Route: intravenous
Route: single
Dose: 20 uCi
Sources:
healthy, 25-35 years
n = 6
Health Status: healthy
Age Group: 25-35 years
Sex: F
Population Size: 6
Sources:
AEs

AEs

AESignificanceDosePopulation
Weight gain
15 mg 1 times / day multiple, oral
Studied dose
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, 10.2-41.9 years
Health Status: unhealthy
Condition: Endometriosis
Age Group: 10.2-41.9 years
Sex: F
Sources:
Overview

Overview

Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
The effect of medroxyprogesterone acetate and norethisterone on the estradiol stimulated proliferation in MCF-7 cells: comparison of continuous combined versus sequential combined estradiol/progestin treatment.
2001
[Hormone replacement therapy in women with arterial hypertension in peri- and postmenopause: hemodynamic effects].
2001
Biphasic versus triphasic oral contraceptives for contraception.
2001
Biphasic versus monophasic oral contraceptives for contraception.
2001
Bone-resorbing cytokines from peripheral blood mononuclear cells after hormone replacement therapy: a longitudinal study.
2001
Detection of estrogenicity by bioassay on the mouse mammary gland in vivo.
2001
Preclinical profiles of progestins used in formulations of oral contraceptives and hormone replacement therapy.
2001 Aug
Pharmacology and toxicology of ethinyl estradiol and norethindrone acetate in experimental animals.
2001 Aug
Effects of hormone replacement therapy and high-impact physical exercise on skeletal muscle in post-menopausal women: a randomized placebo-controlled study.
2001 Aug
Structure of the C-terminal RNA-binding domain of hnRNP D0 (AUF1), its interactions with RNA and DNA, and change in backbone dynamics upon complex formation with DNA.
2001 Aug 31
Omental pregnancy in a woman taking the progestogen-only pill.
2001 Dec
Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate.
2001 Dec
Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study.
2001 Dec
The effects of postmenopausal hormone replacement therapy and oral contraceptives on the endogenous estradiol metabolism.
2001 Dec
The effect of continuous combined hormone replacement therapy on arterial reactivity in postmenopausal women with established angina pectoris.
2001 Dec
Contraceptive vaginal rings.
2001 Dec
Glycaemic control and plasma lipoproteins in menopausal women with Type 2 diabetes treated with oral and transdermal combined hormone replacement therapy.
2001 Dec
Use of solid-phase extraction in various of its modalities for sample preparation in the determination of estrogens and progestogens in sediment and water.
2001 Dec 14
Effective bleeding control and symptom relief by lower dose regimens of continuous combined hormone replacement therapy: a randomized comparative dose-ranging study.
2001 Dec 14
Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor.
2001 Dec 4
Fine structure of prolactin cell of female albino rat as affected by some antifertility drugs--a comparative electron microscopic study.
2001 Feb
Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 microg ethinylestradiol/100 microg levonorgestrel and 20 microg ethinylestradiol/500 microg norethisterone.
2001 Jul
Ovarian function during and after treatment with the new progestagen Org 30659.
2001 Jul
Effects of combined oral hormone replacement therapy on tissue factor pathway inhibitor and factor VII.
2001 Jul
Evaluation of genotoxic potential of synthetic progestins-norethindrone and norgestrel in human lymphocytes in vitro.
2001 Jul 25
Sensitivity to a neurosteroid is increased during addition of progestagen to postmenopausal hormone replacement therapy.
2001 Jun
[Effect of tibolone on vascular markers of human female coronary arteries - comparison with estradiol/norethisterone].
2001 Nov
Effect of norethindrone acetate on hormone levels and markers of bone turnover in estrogen-treated postmenopausal women.
2001 Nov
Temporary discontinuation: a compliance issue in injectable users.
2001 Nov
Effects of oral and transdermal hormone replacement therapy on internal carotid artery pulsatility indices in postmenopausal women. A prospective, randomized, comparative study.
2001 Nov
Drug interactions between oral contraceptives and antibiotics.
2001 Nov
Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial.
2001 Nov
A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia.
2001 Nov
Solution structure and backbone dynamics of an engineered arginine-rich subdomain 2 of the hepatitis C virus NS3 RNA helicase.
2001 Nov 30
Monitoring of solid-phase organic synthesis on macroscopic supports by high-resolution magic angle spinning NMR.
2001 Nov-Dec
Impact of oral contraceptive use on APC-resistance: a prospective, randomized clinical trial with three low-dose preparations.
2001 Oct
A longitudinal study of disturbances of the hypothalamic-pituitary-adrenal axis in women with progestin-negative functional hypothalamic amenorrhea.
2001 Oct
A prospective, controlled study of the effects of hormonal contraception on bone mineral density.
2001 Oct
Effects of HRT on serum levels of IGF-I in postmenopausal women.
2001 Oct 31
[Cross-over comparison of the pharmacokinetics of estradiol during hormone replacement therapy with estradiol valerate or micronized estradiol].
2001 Sep
Bone densitometry in clinical practice: longitudinal measurements at three sites in postmenopausal women on five treatments.
2001 Sep
Determination of circular dichroism and ultraviolet spectral parameters of norgestimate- and other Delta(4)-3-ketosteroid oxime isomers via normal phase HPLC method.
2001 Sep
Validity of radioimmunological methods for determining free testosterone in serum.
2001 Sep
Mammographic density changes during different postmenopausal hormone replacement therapies.
2001 Sep
Progesterone and norethisterone have different effects on tachykinin-like immunoreactivity in rat cortex and striatum.
2001 Sep 15
Triphasic oral contraceptives: review and comparison of various regimens.
2002 Jan
Comparison of reporter gene assay and immature rat uterotrophic assay of twenty-three chemicals.
2002 Jan 15
Comparison of binaural release from forward masking in animals and humans. Electrophysiological studies.
2002 Jan-Feb
Does postmenopausal hormone replacement therapy affect cardiac autonomic regulation in osteoporotic women?
2002 Jan-Feb
Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy.
2002 Jan-Feb
Patents

Sample Use Guides

Secondary amenorrhea, abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology: 2.5 to 10 mg may be given daily for 5 to 10 days to produce secretory transformation of an endometrium that has been adequately primed with either endogenous or exogenous estrogen. Endometriosis: Initial daily dosage of 5 mg for two weeks. Dosage should be increased by 2.5 mg per day every two weeks until 15 mg per day.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Growth of MCF-7 cells was stimulated by norethindrone (10(-8)-10(-5) M), with maximal growth stimulation at 10(-7) M norethindrone after 7 days of treatment
10 - 10000 nM norethindrone stimulates growth of MCF-7 cells
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:11:24 GMT 2023
Edited
by admin
on Fri Dec 15 16:11:24 GMT 2023
Record UNII
9S44LIC7OJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NORETHINDRONE ACETATE
MI   ORANGE BOOK   USP   USP-RS   VANDF  
Common Name English
NORLUTATE
Brand Name English
NORETHINDRONE ACETATE [ORANGE BOOK]
Common Name English
FEMHRT COMPONENT NORETHINDRONE ACETATE
Common Name English
NORETHISTERONE ACETATE [JAN]
Common Name English
COMBIPATCH COMPONENT NORETHINDRONE ACETATE
Common Name English
MYFEMBREE COMPONENT NORETHINDRONE ACETATE
Brand Name English
NORETHINDRONE ACETATE [MI]
Common Name English
NORETHINDRONE ACETATE COMPONENT OF ORIAHNN
Brand Name English
NORLUTIN ACETATE
Brand Name English
LO LOESTRIN FE COMPONENT NORETHINDRONE ACETATE
Common Name English
NORETHINDRONE ACETATE COMPONENT OF LO LOESTRIN FE
Common Name English
NORETHINDRONE ACETATE [USP-RS]
Common Name English
17-Hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one acetate
Common Name English
NORETHINDRONE ACETATE COMPONENT OF ESTROSTEP FE
Common Name English
NORETHINDRONE ACETATE [VANDF]
Common Name English
NORETHINDRONE ACETATE COMPONENT OF ACTIVELLA
Common Name English
NORETHISTERONE ACETATE [EP MONOGRAPH]
Common Name English
NORETHISTERONE ACETATE
EP   JAN   MART.   WHO-DD   WHO-IP  
Common Name English
NORETHYNYLTESTOSTERONE
Common Name English
TRI-LEGEST FE COMPONENT NORETHINDRONE ACETATE
Common Name English
NORETHISTERONE ACETATE [WHO-IP]
Common Name English
17.ALPHA.-ETHYNYL-19-NORTESTOSTERONE ACETATE
Systematic Name English
SH-420
Code English
NORETHISTERONE 17-ACETATE
Common Name English
NORETHISTERONI ACETAS [WHO-IP LATIN]
Common Name English
NORETHINDRONE ACETATE COMPONENT OF COMBIPATCH
Common Name English
NORETHINDRONE ACETATE COMPONENT OF FEMHRT
Common Name English
AYGESTIN
Brand Name English
NORETHISTERONE ACETATE [MART.]
Common Name English
ACTIVELLA COMPONENT NORETHINDRONE ACETATE
Common Name English
19-NORPREGN-4-EN-20-YN-3-ONE, 17-(ACETYLOXY)-, (17.ALPHA.)-
Common Name English
ESTROSTEP FE COMPONENT NORETHINDRONE ACETATE
Common Name English
NORETHINDRONE ACETATE COMPONENT OF TRI-LEGEST FE
Common Name English
ORIAHNN COMPONENT NORETHINDRONE ACETATE
Brand Name English
Norethisterone acetate [WHO-DD]
Common Name English
NORETHINDRONE ACETATE [USP MONOGRAPH]
Common Name English
NSC-22844
Code English
NORETHINDRONE ACETATE COMPONENT OF MYFEMBREE
Brand Name English
NORETHISTERON ACETATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C776
Created by admin on Fri Dec 15 16:11:24 GMT 2023 , Edited by admin on Fri Dec 15 16:11:24 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C702
Created by admin on Fri Dec 15 16:11:24 GMT 2023 , Edited by admin on Fri Dec 15 16:11:24 GMT 2023
PRIMARY
MERCK INDEX
m8056
Created by admin on Fri Dec 15 16:11:24 GMT 2023 , Edited by admin on Fri Dec 15 16:11:24 GMT 2023
PRIMARY Merck Index
MESH
C024262
Created by admin on Fri Dec 15 16:11:24 GMT 2023 , Edited by admin on Fri Dec 15 16:11:24 GMT 2023
PRIMARY
RS_ITEM_NUM
1470004
Created by admin on Fri Dec 15 16:11:24 GMT 2023 , Edited by admin on Fri Dec 15 16:11:24 GMT 2023
PRIMARY
PUBCHEM
5832
Created by admin on Fri Dec 15 16:11:24 GMT 2023 , Edited by admin on Fri Dec 15 16:11:24 GMT 2023
PRIMARY
DAILYMED
9S44LIC7OJ
Created by admin on Fri Dec 15 16:11:24 GMT 2023 , Edited by admin on Fri Dec 15 16:11:24 GMT 2023
PRIMARY
FDA UNII
9S44LIC7OJ
Created by admin on Fri Dec 15 16:11:24 GMT 2023 , Edited by admin on Fri Dec 15 16:11:24 GMT 2023
PRIMARY
DRUG CENTRAL
1963
Created by admin on Fri Dec 15 16:11:24 GMT 2023 , Edited by admin on Fri Dec 15 16:11:24 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
NORETHINDRONE ACETATE
Created by admin on Fri Dec 15 16:11:24 GMT 2023 , Edited by admin on Fri Dec 15 16:11:24 GMT 2023
PRIMARY Description: A white or creamy white, crystalline powder; odourless. Solubility: Practically insoluble in water; soluble in 12.5 parts of ethanol (~750 g/l) TS and in 4 parts of acetone R; sparinglysoluble in ether R. Category: Progestational steroid. Storage: Norethisterone acetate should be kept in a well-closed container, protected from light. Definition: Norethisterone acetate contains not less than 97.0% and not more than 103.0% of C22H28O3, calculated withreference to the dried substance.
ChEMBL
CHEMBL1201146
Created by admin on Fri Dec 15 16:11:24 GMT 2023 , Edited by admin on Fri Dec 15 16:11:24 GMT 2023
PRIMARY
SMS_ID
100000093036
Created by admin on Fri Dec 15 16:11:24 GMT 2023 , Edited by admin on Fri Dec 15 16:11:24 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-132-0
Created by admin on Fri Dec 15 16:11:24 GMT 2023 , Edited by admin on Fri Dec 15 16:11:24 GMT 2023
PRIMARY
WIKIPEDIA
NORETHISTERONE ACETATE
Created by admin on Fri Dec 15 16:11:24 GMT 2023 , Edited by admin on Fri Dec 15 16:11:24 GMT 2023
PRIMARY
EVMPD
SUB03457MIG
Created by admin on Fri Dec 15 16:11:24 GMT 2023 , Edited by admin on Fri Dec 15 16:11:24 GMT 2023
PRIMARY
NSC
22844
Created by admin on Fri Dec 15 16:11:24 GMT 2023 , Edited by admin on Fri Dec 15 16:11:24 GMT 2023
PRIMARY
CAS
51-98-9
Created by admin on Fri Dec 15 16:11:24 GMT 2023 , Edited by admin on Fri Dec 15 16:11:24 GMT 2023
PRIMARY
RXCUI
31983
Created by admin on Fri Dec 15 16:11:24 GMT 2023 , Edited by admin on Fri Dec 15 16:11:24 GMT 2023
PRIMARY RxNorm
DRUG BANK
DBSALT000129
Created by admin on Fri Dec 15 16:11:24 GMT 2023 , Edited by admin on Fri Dec 15 16:11:24 GMT 2023
PRIMARY
CHEBI
7628
Created by admin on Fri Dec 15 16:11:24 GMT 2023 , Edited by admin on Fri Dec 15 16:11:24 GMT 2023
PRIMARY
EPA CompTox
DTXSID4023381
Created by admin on Fri Dec 15 16:11:24 GMT 2023 , Edited by admin on Fri Dec 15 16:11:24 GMT 2023
PRIMARY
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
sum of NORETHISTERONE ACETATE impurities D and G: maximum 0.2 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
sum of NORETHISTERONE ACETATE impurities D and G: maximum 0.2 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY